Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sure would have been!
I see 50,000 at 0.0143.
Guess that was Dean's.
.0431 would have been a nice bump on the chart
I've seen this before which is why I follow two different platforms for trades. On the E*TRADE platform. You're right it does show it as a sale (red)but when we check trades here on this platform, it shows it as a buy and it's in green. I'm just guessing but since it came in at a lower price, than your first trade and it shows up red it was the company raising money? Be happy for the lower price. :)
Purchased 70,000 shares today. First part 50,000 filled @ .0431 second part 20,000 filled @ .014105 and shows as a sale. Hmm
Not good for charts when they do that crap.
The share volume has picked up a lot over the last month. A substantial increase in volume seems like it could be a good sign.
True!
I was also hoping for 2 customer announcements this week from Verséa Ophthalmics. Guess I'm greedy or impatient.
I'm not complaining and I'm definitely happy with the progress shown over the past 2.5 months.
HOWEVER
If we only get 1 announcement per week it will take 120 weeks for AXIM to become cash-flow positive - UNLESS we receive CLIA waivers from the FDA sometime before then.
Not investment advice.
Don't invest money needed for food or rent.
Have a good weekend.
CLIA waiver could be months or years away...we wouldn't know because AXIM isn't giving CLIA updates.
OMNI EYE CENTER - LASERVISION from Edmond, Oklahoma is a second generation practice that has been in business for more than 30 years. 4 doctors on staff.
Not many more details to share.
I think a previous post i shared said over 48,000 eye care locations in US. AXIM needs only about 120 locations to become cash-flow positive. Once CLIA Waiver approvals are received this little company can grow sales and revenue very quickly.
New Customer from Edmond Oklahoma.
I will look at the details this evening.
Have a good day.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitan-tpoc-ded-activity-7170765029711958016-CaBo?utm_source=share&utm_medium=member_android
Links related to our company and partners.
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Lactoferrin
#TotalIgE
I still anticipate a block of Form 4's to come out when the time is right and it does seem very near.
Checked for the 10K A today and realized that its due at the end of March then a 10 day extension is possible until April 10. I had an accelerated filer in mind when I posted that it was due today. No matter, something is happening with the increasing interest in the stock.
Appreciate your thoughts as usual Tex. I have been wondering about the NPTX ticker being used for Versea not a direct combination with AXIM. Of course all three of the companies would own shares of the other entities and have an even increased note note relationship. I do not see AXIM as part of a direct combination with the possible exception of Neuropathix although that puzzle piece seems to fit MJNA better.
Its been a while since I researched the birth of Versea but one part that I recall is that the same crew started a related company previously and ramped it up into a successful acquisition. They have a history of operating that way. The evolving enterprise and some of their PR seems to suggest that they are on a track to go public.
I do think it would be difficult for AXIM to merge with Verséa Health. AXIM would probably want it to be a 50-50 merger. Verséa Health would probably want a bigger chunk than 50%.
On the other hand the AXIM patents and cancer research might be the glue that could make a 50-50 merger at least attractive.
It is fun to speculate when we have a slow news week. Actually the big picture the past 2 months has produced a ton of big news items.
Auer Precision agreement
Weekly customer announcements
Additional order of reader machines.
I do think Catalina Valencia has been contributing a lot behind the scenes the last few years. However my guess is the leadership after Mr Huemoeller will be someone younger.
Maybe from that angle a merger with Verséa Ophthalmics would work in the best interest of everyone. Verséa has some younger leaders that could step in and help build out a stronger portfolio of products. Everyone wins.
I agree with you about Verséa going public. It seems like that's what Biotech companies do. Build some products and sell to the big players.
I'm not sure if AXIM and Verséa could combine companies where everyone would be happy with their share. But the 2 companies might be stronger together.
I don't know anything about NPTX.
The Tarsus name came up from the reactions to LinkedIn posts.
With regard to the trading Tex the volume after both of the dips in February was quite dramatic. Almost as if insiders had submitted note conversion requests to the company and could finally buy without impacting the plan. Its also possible that there was shorting activity involved in those dips that needed to be covered. You gotta love Catalina. Knowing that all of this was coming she was willing to purchase her 10M shares at 3 cents after she scored the DED relationship with her old cronies. She was willing to fund the company at that level in exchange for being able to purchase such a large block of shares off market. Either way she is a big believer. Cat was willing to put down serious change while her peers paid peanuts for options and signed free deals to be the recipients of put options. Maybe that was her buy in price to become a family member. I see her running this show a few years down the road after the company is solidly launched and the old family members have made their money.
Now that is an interesting and speculative take on things Tex. As you have read, I have been thinking that perhaps AXIM helps Versea go public, possibly using the family NPTX ticker and Neuropathix becomes part of AXIM or MJNA Something has to happen to it because I doubt that the Cross family, Dean P or MJNA would benefit from it remaining in its current condition long term. Weighing in your comments I am still quite certain that based on the history of the Versea principals they are quite likely to go public soon with or without the optics business. I am predicting that they will retain it but everything has its price. When I used to work in marketing I used to say that everything that is not screwed down to the building is for sale for the right price and if you really wanted it the building was for sale too.
Tarsus Pharmaceuticals (TARS) also in the EyeCare space just raised $100 Million. Their current revenue of $17.5 million seems pretty low to justify such a rich share price. Doesn't seem to add up.
Could the AXIM + Verséa team follow the same path as Tarsus? Surely Verséa Health would not sell their Ophthalmics division right here at the beginning of a growth story would they? Merger of Equals? Could Verséa need cash? I don't know.
It seems like builders would want to sell a product after it is finished, like a house. The Verséa Ophthalmics + AXIM foundation is not even dry yet. The house still needs to be built. Catalina Valencia didn't buy millions of shares of AXIM to sell away for a loss did she?
It just seems like the more LinkedIn posts shared by Verséa Ophthalmics the more people at larger companies in the eyecare space have a reaction to those posts. Including people from Tarsus and Novartis and Bausch and Lomb among others.
3.6 million shares yesterday. That's only about $55,000 on the buy side and the sell side but it was an interesting looking day.
Lots of round numbers throughput the day. 2.5 million shares in one 10 minute time slot in the morning. But then another million shares broken down into large round chunks.
Maybe the story is starting to get out there? I wonder if a doctor or 2 or 10 bought some shares yesterday?
Right now as far as the share price, I will gladly take "interesting" over nothing. On the business side we are watching a growth story in slow motion. At some point we may wish we would have bought more cheap shares when they were available.
Good luck to all.
Not investment advice.
I appreciate your trust. All of your posts since 2012 have been to ask me questions! I think that both companies will do as well. Three years ago I thought that by now they would be doing very well. Good things come to those who wait.
Blue Skys, Where do you see AXIM and MJNA going in the coming months and years?
It will be interesting to see of it is AXIM or the need to drive the sister stocks that finally turns this around. Marijuana rescheduling or descheduling could create a business cast to increase the valuation of the massive AXIM ownership of MJNA when that stock is fundamental driven. I just wish I understood the game plan for the company formerly trading as NPTX. I am still guessing that ticker will have a higher purpose in the grand scheme.
JH is really an expert in controlling the stock price. He continues to amaze me with his finesse in getting the best note conversion and sucking the value out of MJNA all at the same time. I expect that some day he will show case that talent in a more desirable direction. It has taken him years to knock it down this low.
I just noticed that Verséa Ophthalmics team member Rahim Hirji is also managing Clinical Training and Implementations. Jessica Barr has Director in her title. Rahim is a VP.
Point being, multiple people help with new Implementations even though Jessica Barr is the one who puts her signature on the final approval.
SCIENTIST ALIM SEIT-NEBI
˜======================
BTW, when it is a slow news day I like to use LinkedIn to see what AXIM scientist Alim Seit-Nebi is posting on LinkedIn. And/Or what posts he likes or comments on. Alim has not posted for some time, but here are a few posts from other people he has found interesting in the past week. All related to cancer research.
I only share these because i believe the cancer research angle still exists at AXIM. Maybe in the future we will hear of cancer tests from tear drops??? I don't know, but maybe Alim knows.
BTW, IHUB gets confused on these links to LinkedIn. You might need to exit IHUB after looking at each link so you can view the next link.
https://www.linkedin.com/posts/megan-conlon-phd-91369889_new-immune-cell-engagers-for-cancer-immunotherapy-activity-7167955333150179328-auk3?utm_source=share&utm_medium=member_android
https://www.linkedin.com/posts/science-magazine_scienceperspective-activity-7167888577450754048-gSIG?utm_source=share&utm_medium=member_android
https://www.linkedin.com/posts/joseph-steward_spatial-analysis-reveals-combinative-role-activity-7166794645203599360-kp6r?utm_source=share&utm_medium=member_android
I suppose AXIM is just a hobby until the share price agrees with what appears to be a growth story that very few know about.
My posts are not meant as investment advice, but they are based on my own research. In my opinion don't invest money needed for food or rent or even the pursuit of happiness. Maybe when expectations fall away, AXIM will surprise a few people.
Until then, have a blessed day.
Thank you for all your hard work posting this great info. Watching this one.
Thank you for all your hard work posting this great info. Watching this one.
What I noticed about today's announcement by Verséa Ophthalmics on LinkedIn.
There must be a very rapid consolidation happening in the eyecare space. EyeSouth Partners did not make the list of the 2023 Top Fifty largest Eyecare Networks report from June 2023. However looking at the details shared in the following announcement from December 19th 2023 EyeSouth Partners would have been almost right in the middle of the Top 50 largest Eyecare networks with 180 locations.
Consolidation should be very good for AXIMs and Verséa Ophthalmics roll-out plans.
HIGH LEVEL SUMMARY:
EyeSouth’s affiliate network consists of 39 practices with over 300 doctors providing medical and surgical eye care services at more than 180 locations including 20 surgery centers throughout Georgia, Texas, Louisiana, Florida, Tennessee, Ohio, Kentucky, Pennsylvania, Alabama, Illinois, North Carolina, and South Carolina.
LINK TO ARTICLE:
EyeSouth Partners Affiliates With Atlantic Eye Institute, Representing The Network’s 39th Affiliation and Ninth in Florida - https://www.eyesouthpartners.com/news/eyesouth-partners-affiliates-with-atlantic-eye-institute-representing-the-networks-39th-affiliation-and-ninth-in-florida/
Not investment advice.
Have a good day.
Another customer announced this morning
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitan-tpoc-ded-activity-7168228316540317696-VXJS?utm_source=share&utm_medium=member_android
Have a good day.
25,000 device installations worldwide.
Ophthalmology Breaking News.
Maybe not an "Apples to Apples" comparison to AXIM. However AXIM/Verséa are selling to the same offices as Optos.
I paid $30 to have pictures taken of my retinas last time I had my eyes checked.
Advantages:
*** No pupil dilation
*** better image capture.
*** Doctor keeps image for future reference
Win-Win.
25,000 global device installations.
The AXIM/Verséa Ophthalmics test-reader device is not a 1-trick pony. Two existing FDA cleared 510K tests. MMP-9 510K announced as available in 15 months. Maybe other tests to follow.
https://ophthalmologybreakingnews.com/optos-celebrates-device-installations-worldwide-clinical-studies
Optos's unique position in the market is highlighted by its proprietary single-capture, 200-degree, ultra-widefield retinal imaging technology. This technology is pivotal for diagnosing and managing a broad spectrum of ocular conditions, enhancing the detection and diagnosis processes.
150 tests per month is only 75 customers per month
75 customers × 2 tests =150 tests per month.
15 to 20 office days per month allows for a 4 or 5 working days per week.
5 clients per day with 15 working days per month.
4 clients per day with 20 working days per month.
These numbers are probably on target for smaller offices, but might be conservative estimates for offices with multiple doctors or offices within a larger network of eye surgery clinics.
"AXIM expects clinics to perform approximately 150 tests per month."
I noticed two things from the announcement last week.
"Most clinics require at least two readers to efficiently perform both tests."
This is new information and having 2 readers allows both tests to be administered at the same time. Potentially increasing the number of tests used per day.
"AXIM expects clinics to perform approximately 150 tests per month."
For some reason I thought the original number was 300 tests per month. If the new number is 150 tests per month then Verséa needs to sign up 120 doctor offices for AXIM to become cash-flow positive instead of just 60 locations. Inflation on labor may push this number higher, but let's stay with 120 locations for now.
150 × $10 × 0.70 × 120 = $126,000 per month.
150 tests per month
$10 AXIM receives per test
0.70 percent after manufacturing cost.**
120 locations
$126,000 per month before scientists get paid and rent and bills and other expenses are paid.
** Cost per manufacturing tests was originally projected to be 30% but we don't have any new information after Auer Precision was signed as contract manufacturer.
Verséa Ophthalmics has had a number of announcements of paying customers the last 2 minths. Two announcements mentioned 3 new locations each. Let's estimate 12 to 15 current locations are currently selling our tests.
We are still months away from being cashflow positive at this current pace.
CLIA Waiver approval is still the goal and is required before the current narrative changes much.
Good luck to all.
Not investment advice.
Since the AS increase was posted on Silver Flume during Q4, the derivative liability insufficient shares accounting paradigm must be resolved in the 2023 10K and the new OS must be revealed. With the 10 day extension we should know the new OS and note conversion details, if applicable, by Monday March 11, 2024. That will have been a long time coming. I can only guess that some of the recent selling is based on that in addition to the recent news (that I consider to be bullish) regarding the legal settlement for the DED testing technology. We will soon see how accurate our squirrel friend was with his prediction of an OS under 350M shares at launch. The last time we had a series of form 4's from insiders converting some of their variable convertible notes and I believe Blake Neil Schroeder converting all of his notes we had quite a rally in the stock price as it was taken as a management vote of confidence on the future of the company. I have crunched some numbers regarding what I think the OS will be but I am going to remain silent on that issue at least until that Monday nears. Depending on external factors the results could be released any time between now and then. So many pieces to assemble here. Possibly a one two punch with the Wavier issued just before or after the 10K.
Getting close to that .02! A little good news gave a bounce.
Thanks for sharing!! I had not noticed this.
This is the official announcement from Verséa Ophthalmics LinkedIn page about the first AEG Location: Crown Vision Center from last week.
The Verséa Ophthalmics team was very busy last week. They had a booth at 2 different trade shows last week. One in Tampa "Telling it like it is" February 15th - 18th and the other in Atlanta Georgia by Dry Eye University 2.0 February 16th - 17th.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_tpoctitan-tpoc-ophthalmics-activity-7165691596988989440-ec0C?utm_source=share&utm_medium=member_android
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Lactoferrin
#TotalIgE
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
9:06 AM ET 2/20/24 | Dow Jones
February, 20, 2024 -- (AXIM Biotech) --
(NewMediaWire)
The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader
SAN DIEGO, CA - (NewMediaWire) - February 20, 2024 - AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solutions development company, announced today that the Company has received an additional order for its electronic readers designed to analyze both of the Company's proprietary diagnostics assays from its commercialization partner Verséa Ophthalmics. The re-order of readers marks a pivotal milestone in AXIM's expanding clinical presence and re-occurring revenue opportunity.
AXIM's commercialization partner Verséa Ophthalmics has been ramping up sales of the Company's proprietary, FDA-cleared ocular diagnostic assays in recent months. Both its ocular T-POC TOTAL IgE Immunoassay and T-POC LACTOFERRIN Immunoassay Kits use an electronic reader to analyze the results of tear samples at the point-of-care. Verséa Ophthalmics' reorder of these readers indicates an impending clinical expansion of AXIM's diagnostic program. Most clinics require at least two readers to efficiently perform both tests. Once a clinic receives a reader it must undergo a validation prior to its clinical use. The recent reorder reflects the successful clinical validation and implementation of the reader platform. AXIM expects clinics to perform approximately 150 tests per month. The reorder made by Verséa indicates that they have sold and/or disbursed the majority of their original inventory of readers to clinics and foresees additional interest in the platform from new clinics.
"Sales of our diagnostic platform which is based on a digital reader that allows for quantification of tear biomarkers, demonstrates momentum as shown by this re-order," said John Huemoeller II, CEO of AXIM Biotechnologies. "As Verséa continues to expand sales, we will work with our recently announced manufacturing partner Auer to scale manufacturing to not only meet demand but improve efficiency wherever possible. Our platform was designed to create a re-occurring revenue stream for AXIM as the tests are one-time-use and have associated Medicare CPT codes. The more clinics we are able to add, the more monthly re-occurring revenue is produced for AXIM. We are extremely pleased by the positive reception Verséa Ophthalmic's is getting from clinicians and look forward to fulfilling this re-order quickly, enabling a whole new set of clinics to begin testing on our platform."
Both of AXIM's ocular diagnostic assays were designed to provide clinicians with a tool to both diagnosis and properly treat Dry Eye Disease (DED) at the point-of-care, a previously unavailable solution. The tests quantitatively measure two different indicators in patient tear samples which have been shown to assist clinicians in proper diagnosis of DED, and render result in nine minutes. DED is historically under or mis-diagnosed with estimates that between 5%-15% of the entire US population show symptoms consistent with DED. AXIM's platform seeks to close this diagnosis gap through its affordable, accurate, and point-of-care platform.
For more information on AXIM's diagnostic solutions or to speak with someone at AXIM's commercialization partner Verséa about adding these innovative solutions to your clinic, please visit: https://www.versea.com/divisions/ophthalmics/
About AXIM(R) Biotechnologies
Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.
Forward-Looking Statements
The statements made by Axim Biotechnologies Inc., in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim's eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company's diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim's SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT
AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422
Investor Relations
investors@aximbiotech.com
888-759-0844
Copyright (c) 2024 TheNewswire - All rights reserved.
> Dow Jones Newswires
February 20, 2024 09:06 ET (14:06 GMT)
Podcasts - Surprisingly there are many podcasts dedicated to the topics of Ophthalmology and Dry-Eye Disease. Who knew??? This post is not really about AXIM but is about Dry Eye Disease. Eye doctors really do need quantitative Dry Eye Disease tests.
Dr Periman was the host of a 3 part miniseries about the International Perspective on dry eye disease. This was from the CRST podcast channel. Actually Dr Laura Periman is on the AXIM EYE advisory board. So I guess there is a small connection to AXIM.
http://castbox.fm/app/castbox/feed/e389a8be15915ab25859e725ab09432ce10cf7e9/track/542849816
http://castbox.fm/app/castbox/feed/e389a8be15915ab25859e725ab09432ce10cf7e9/track/544975333
http://castbox.fm/app/castbox/feed/e389a8be15915ab25859e725ab09432ce10cf7e9/track/546646474
Cut/Paste from the axim eye website.
LAURA M. PERIMAN, MD
Dr. Periman brings 30 years’ experience in medicine, the last 20 of which include her clinical practice specializing in ocular surface disease and dry eye disease (DED). She serves as Founder and Director of Dry Eye Services and Clinical Research of the Seattle-based Periman Eye Institute. Additionally, she has served as a principal investigator in ophthalmic clinical research primarily centered on ocular surface disease innovations including neural stimulation for treating DED, novel topical therapeutics as well as innovative procedures such as IPL, Radiofrequency and more
EyeCare Partners Inc was listed at number 5 on this 2023 list with 700 locations.
On the same 2023 list AEG was listed at number 11 with 350 locations. I saw a link to CEO on Google showing more than 400 locations for AEG.
https://www.visionmonday.com/vm-reports/top-50-retailers/article/vms-2023-top-50-us-optical-retailers/
Imagine this. What if I could drop by the eye center at the local LensCrafters or Pearl Vision or EyeCare or AEG or Costco or SAMS or Walmart and get screened for PD with the AXIM Tear-based Point-of-Care Parkinson Disease test? AXIM and Verséa Ophthalmics and Auer Precision can make that happen within 2 years.
Maybe 12 to 15 months down the road AXIM has the MMP-9 test as the third FDA cleared tear based Point-of-Care test. Then the Parkinson Disease test.
Hey AXIM: What other diseases can be scanned for in a tear drop?
More than 48,000 brick-and-mortar optical retail locations in business.
www.visionmonday.com/business/article/us-optical-retail-market-estimated-at-765-billion-in-the-vision-councils-first-comprehensive-market-insights-report/#:~:text=Here%20are%20some%20of%20the,optical%20retail%20locations%20in%20business
Website has link to PDF showing the top 50 retailers in 2023 and 2022.
AEG was listed at number 11 with 350 locations. I saw a link to CEO on Google showing more than 400 locations for AEG.
https://www.visionmonday.com/vm-reports/top-50-retailers/article/vms-2023-top-50-us-optical-retailers/
AEG posted that 3 locations are currently training to use #TPOC
If original rollout numbers of 300 initial tests per location then add $9000 to AXIM accounts receivable.
https://www.linkedin.com/posts/aeg-vision_aegvision-aegvisionpilots-activity-7163999586531962880-y6lk?utm_source=share&utm_medium=member_android
Their website mentions over 400 locations total.
AEG Vision has over 400 locations.
https://www.aegvision.com/about/
Links related to our company and partners.
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Lactoferrin
#TotalIgE
I am impressed! I didn't think that there were more shares to be shaken out after all the previous events. I suspect that this is the last of it. Its good for the stock although I feel for those who are selling. It reminds me of that old truism that most jailbreaks come right before the end of a prisoners sentence.
Another customer selling the AXIM tests in their practice.
https://www.linkedin.com/posts/rebecca-chandler-89b1ab45_aegvision-aegvisionpilots-activity-7164335314365329408-bgXC?utm_source=share&utm_medium=member_android
#VerséaOphthalmics
#VerséaHealth
#TPOC Tear based Point-of-Care
#DryEye #Diagnostics #Quantitative
#Lactoferrin #TotalIgE
#TPOCTITAN #TPOCTITANS
#AuerPrecision ISO Certified
#ISO9001 #ISO13485
#AXIMBIOTECH
#AXIMEYE #DryEye
#Lactoferrin
#TotalIgE
Once all the financial crap gets flushed out and we have a good idea of how many shares are actually outstanding maybe the share price starts to fly.
Definitely increased volume last 2 days. Not a huge dollar amount yet, but maybe a few folks making a $20000 bet on AXIM???
I expect it to be covered in the 10K as normally significant events up to the date of the quarter are disclosed. I expect JH to request the 10 day extension to flile the report so I expect it on April 10.
Good Bad or Ugly, the settlement announced yesterday probably means AXIM will have all the debt converted to shares before the 2023-Year-End Report is released in April. Right???
However it is Q1 2024 already, so i guess the worst-case is the Q1 2024 10-Q report will definitely have a clear picture of the number of shares used up by debt conversion and Derivative Liability insufficient shares.
I sure hope Mr Kurt Phinney is still under contract and helping with the CLIA Waiver process and helping with the MMP-9 quantitative test submission to the FDA. The Parkinson Disease Point-of-Care test would fit great in the marketing agreement with Verséa Ophthalmics. Could AXIM be selling 4 FDA cleared Point-of-Care tests just 12 to 15 months from now??
Verséa Ophthalmics will be in Booth 53 in Tampa this weekend selling AXIMs Dry Eye Disease tests. My previous post said Atlanta Georgia but apparently the conference is in Tampa.
https://www.linkedin.com/posts/vers%C3%A9a-ophthalmics_vers%C3%A9a-ophthalmics-is-proud-to-be-an-exhibitor-activity-7163879915669422080-9k6s?utm_source=share&utm_medium=member_android
Unlike currently available serological COVID-19 tests that detect an antibody response to the virus, AXIM’s rapid 10-minute test measures a specific subpopulation of antibodies to block binding of the virus to host cell receptors. While there are expensive, time consuming laboratory tests that measure neutralizing antibodies, NeuCovixTM differs in that it is a portable, low cost, rapid point-of-care test with results in 10 minutes.
“We are hopeful our test fills an important need in these uncertain times. While other tests merely show whether someone was infected with coronavirus, we took it a step further by creating a test that stratifies individuals into those who have neutralizing antibodies, which are essential in preventing reinfection, and those who don’t. The test can be deployed for point of care use in convalescent plasma transfusions to severely ill patients and for evaluating efficacy of upcoming vaccines in generating protective antibodies,” said Sergei Svarovsky, PhD, MBA, AXIM’s CSO and co-inventor of NeuCovixTM.
An immediate application of NeuCovixTM, a point-of-care test, is to measure levels of neutralizing antibodies in convalescent plasma so that plasma with the highest levels of neutralizing antibodies can be identified and administered to patients fighting COVID-19. Without this knowledge, many patients could be undertreated with non-neutralizing plasma and may not benefit from this treatment.
Another application of NeuCovixTM is to help ensure that vaccines elicit high levels of neutralizing antibodies. When a vaccine is available, manufacturers can employ the NeuCovixTM rapid, point-of-care test to evaluate protective immune responses in vaccine recipients.
AXIM® Biotech CEO John W. Huemoeller II commented, “Our goal was to make this test, accurate, fast and relatively inexpensive so it could serve as an ‘Immunity Passport port™’ for vaccine developers around the world as they begin larger Phase II and III clinical trials. We are optimistic that NeuCovixTM will be widely used, becoming the gold standard in assessing levels of immunity.”
Doug Lake, Ph.D. and co-inventor of NeuCovixTM commented, “Everybody who recovers from COVID-19 makes antibodies against the virus, but since all antibodies are not created equal, you really want to know if the antibodies you make neutralize the virus. People who recover want to make sure they are protected from re-infection and that they won’t infect others.”
AXIM also announced the filing of a pre-Emergency Use Authorization Application (EUA) and has already initiated dialogue with the FDA in order to finalize its EUA submission. The intellectual property relating to the novel serological test is the subject of Provisional Patent Application No. 63/023,646 “Convalescent Plasma Testing and Treatment” filed on May 12, 2020.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The Company is also developing novel antibodies for therapeutic and diagnostic uses for oncological therapeutics. For more information, please visit www.AXIMBiotech.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |